

## EXO-NET PRESENTED AT VIRTUAL ANZSEV SYMPOSIUM

**Melbourne, Australia, 10 November 2021:** BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that Dr Emily Stein, BARD1 Technology Director and founding scientist of the Molecular Nets technology, will be presenting about its EXO-NET<sup>®</sup> exosome capture tool at the virtual Australian & New Zealand Society for Extracellular Vesicles (ANZSEV) Symposium today.

*Authorised for release by Company Secretary, Tony Di Pietro.*

- ENDS -

### COMPANY CONTACTS:

**Dr Leearne Hinch**  
CEO  
E [leearne@bard1.com](mailto:leearne@bard1.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-Executive Chairman  
E [geoff.cumming@bard1.com](mailto:geoff.cumming@bard1.com)  
M +61 417 203 021

### ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is an Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see [www.bard1.com](http://www.bard1.com) and [www.exo-net.com](http://www.exo-net.com).